Načítá se...

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks

OBJECTIVE: We recently reported that after 26 weeks, exenatide once weekly (EQW) resulted in superior A1C reduction, reduced hypoglycemia, and progressive weight loss compared with daily insulin glargine (IG) in patients with type 2 diabetes who were taking metformin alone or with sulfonylurea. This...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Diamant, Michaela, Van Gaal, Luc, Stranks, Stephen, Guerci, Bruno, MacConell, Leigh, Haber, Harry, Scism-Bacon, Jamie, Trautmann, Michael
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2012
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3308312/
https://ncbi.nlm.nih.gov/pubmed/22357185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc11-1233
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!